Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025
Ella Day | May 12, 2025 | News story | Research and Development | Cardiology, Novo Nordisk, Obesity, Ozempic, cardiometabolic conditions, heart disease, obesity, semaglutide
Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming 32nd European Congress on Obesity (ECO). Central to the announcement will be findings related to semaglutide, a GLP-1 receptor agonist developed as a treatment for obesity and related cardiometabolic conditions.
Semaglutide will be a key focus, alongside data on the societal costs of obesity and the challenges facing adolescents with the condition.
Novo Nordisk’s claims to the efficacy of semaglutide will be supported by a range of real-world evidence studies, analysis of its cardiovascular outcomes trial, SELECT, as well as part 1 of the phase 3 ESSENCE trial in metabolic dysfunction-associated steatohepatitis (MASH).
Marketed under the brand names Wegovy, Ozempic and Rybelsus, semaglutide mimics the GLP-1 hormone to support weight loss and improve cardiometabolic health when combined with lifestyle interventions.
Stephen Gough, senior vice president and head of chief medical officer at Novo Nordisk, said: “Our semaglutide data presented at ECO, including its impact on weight loss in a real-world setting and its early clinical effect on cardiovascular events and death, significantly adds to the growing body of evidence showing the value of semaglutide to individuals, healthcare systems and society.”
He added: “Without effective interventions, the global burden of obesity and its complications will continue to rise.”
The full results are being presented between 11 to 14 May in Málaga, Spain, offering further insight into semaglutide’s potential beyond weight loss.
Ella Day
12/5/25
Related Content
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
Lilly reports positive results from trial of obesity candidate
Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, …
